Skip to main content

Advertisement

Table 9 Results from the cost-utility analysis from the health care perspective excluding the development and implementation costs

From: Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants

  Best DMP VS worse DMP* Incremental costs Incremental QALYs Mean ICER % of 5000 simulated ICERs per quadrant in the CE plane
      NW NE SW SE
CVR-primary# 7 VS 4 −407 0.003 −136,077 3 7 39 51
(330) (0.021)
CVR-secondary$ 1 VS 3 −863 0.012 −73,013 4 14 17 65
(961) (0.015)
CVR-both 2 VS 8 −326 0.005 −67,145 10 10 28 52
(388) (0.016)
COPD 1 VS 4 1,574 0.009 170,390 32 45 12 11
(1,985) (0.053)
DMII 1 VS 3 −430 0.013 −31,942 3 11 12 74
(402) (0.013)
  1. *most effective is defined based on the highest incremental QALY and the reverse; #primary prevention for CVD; $secondary prevention for CVD; ICER: incremental cost-effectiveness ratio; CE: cost-effective(ness); best is defined as most effective based on QALYs and worse as the least effective based on the same measurement; the numbers correspond to the DMP numbers in Table 4.